No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer-Reference-Cited by-同舟云学术

No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer

Published:2023-05 Issue:5 Volume:25 Page:521-532
ISSN:1365-182X
Container-title:HPB
language:en
Short-container-title:HPB

Author:

Liu Hao^ORCID,D'Alesio Mark^ORCID,AlMasri Samer,Hammad Abdulrahman^ORCID,Desilva Annissa,Lebowitz Steven^ORCID,Rieser Caroline,Ashwat Eishan,Hampton Erica,Khachfe Hussein,Laffey Mckenna,Singhi Aatur,Bahary Nathan,Lee Kenneth,Zureikat Amer,Paniccia Alessandro^ORCID

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference18 articles.

1. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy;Sohal;JNCI Journal of the National Cancer Institute,2014

2. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer;Ferrone;Ann Surg,2015

3. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas;Downs-Canner;J Surg Oncol,2015

4. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma;Moffitt;Nat Genet,2015

5. Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters;Dauer;Pancreatology,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer;Surgery;2024-10

2. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery;Annals of Surgical Oncology;2024-02-06

3. Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases;Annals of Surgical Oncology;2024-01-25

4. Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma;Cancers;2024-01-20

5. Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future;Seminars in Liver Disease;2024-01-11